Utility of human iPSC derived CMs for preclinical safety assays and disease modelling
Presentation
Presentation title
Utility of human iPSC derived CMs for preclinical safety assays and disease modelling
Author
Sarah Williams, PhD, Senior Scientist, Metrion Biosciences
Overview
This talk was presented by Dr Sarah Williams at the Axol Metrion Interactive Stem Cell Forum held in May 2018. This project received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 Research and Innovation Program.
Please contact us if you would like any further information regarding our cardiac translational assays.
Background
Applications of human iPSC derived cardiomyocytes
Human induced pluripotent stem cell derived cardiomyocytes (iPSC CM) can be differentiated from healthy or diseased donors.
Many applications of iPSC CM including:
- Study of channelopathies e.g. long QT syndromes
- Development of patient specific pharmacology
- Stem cell therapies
- Drug screening and preclinical safety assessment
To successfully utilise iPSC CM as a model system they need thorough functional characterisation.
CM at Metrion and the Aims of electrophysiological characterisation – Slide 7
Other recommended presentations
- Validation of an impedance-based phenotypic screening assay able to detect multiple mechanisms of chronic cardiotoxicity in human stem cell-derived cardiomyocytes
- M-type K+ channels in nociceptive pathways: physiological roles and therapeutic potential
- In depth profiling of human iPSC cardiomyocytes: From electrophysiology to phenotypic assays
- Therapeutic potential of activators of two-pore domain ion channels
- Modulation of voltage-gated calcium channels in disease
Let’s work together
What are your specific ion channel and assay needs?
If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.